US Patent

US8557283 — Controlled release formulations of levodopa and uses thereof

Method of Use · Assigned to Impax Laboratories LLC · Expires 2028-12-26 · 3y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects controlled release formulations of levodopa, including a multiparticulate formulation with a controlled release component, carboxylic acid component, and immediate release component.

USPTO Abstract

The current invention provides a controlled release oral solid formulation of levodopa comprising levodopa, a decarboxylase inhibitor, and a carboxylic acid. Also provided by this invention is multiparticulate, controlled release oral solid formulations of levodopa comprising: i) a controlled release component comprising a mixture of levodopa, a decarboxylase inhibitor and a rate controlling excipient; ii) a carboxylic acid component; and iii) an immediate release component comprising a mixture of levodopa and a decarboxylase inhibitor.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1645 — Sinemet Cr
U-1645 — Sinemet Cr
U-219 — Sinemet Cr
U-219 — Sinemet Cr

Patent Metadata

Patent number
US8557283
Jurisdiction
US
Classification
Method of Use
Expires
2028-12-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Impax Laboratories LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.